| Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R ...
SUNNYVALE, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Accuray Incorporated (NASDAQ: ARAY) , a global leader in the field of radiosurgery, today announced that its CyberKnife(R) Robotic Radiosurgery System has been used to treat more than 4,000 lung cancer patients worldwide. The company also reported that more than 40,000 patients in total have been treated with CyberKnife radiosurgery for tumors throughout the body. In April 2007, Accuray announced that the number of lung tumor patients treated with the CyberKnife System had surpassed 2,000. In the span of seven months, that number doubled, demonstrating the growing clinical adoption of this treatment modality in lung cancer care. This significant growth is due in part to the increasing availability of Accuray's unparalleled lung cancer treatment offerings at CyberKnife centers.
Bipolar disorder: More than a punchline
That's not truth in labeling, the comedian said, turning the package around. On that side the brand name was "Bipolar." At least people who have bipolar disorder weren't laughing. A powerful stigma is attached to being bipolar. "The stigma is that everybody who's bipolar could go wild," said Sue Floyd, a board member of the Depression Bipolar Support Alliance in Cape Gir?ardeau. Many people don't understand the disorder and its varying severity. Their first impulse is to stay away from someone who's bipolar. People who have the disorder fear that reaction. That's one of the problems with Leno's joke. "If people are laughed at, it's just going to drive them back in their shell," said Dr. Kishore Khot, a psychiatrist at the Community Counseling Center in Cape Girardeau.
Extracellular protein sensitizes ovarian cancer cells to chemotherapy
Scientists have uncovered critical new details about the mechanisms that modulate the response of ovarian cancer cells to chemotherapy. The research, published by Cell Press in the December issue of Cancer Cell, helps to explain why many patients develop resistance to the taxane class of drugs and may lead to improved treatment of ovarian cancer. Full story � .
|
